A recent study highlighted the efficacy of JNJ-75276617 (with a patented structure) with a significant preclinical activity against OCI-AML3 cell lines and primary AML cells by disrupting the menin/KMT2A protein complex and the resulting data support the first-in-human study to evaluate JNJ-75276617 as monotherapy for patients with R/R AML with KMT2A or NPM1 alterations (NCT04811560) [117]. This evidence concerns the gene KMT2A and acute myeloid leukemia.